NCT Number: NCT02066103
Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients
Assess the safety and feasibility of local oncological drug delivery into the bronchial wall after recanalization of subjects with malignant airway obstruction. Safety and feasibility (technical success) will be assessed.
This localized delivery is intended as an adjunct therapy and all subjects will receive standard of care oncology therapy as determined by their treating physicians.
Looking for future studies?
Notify MeKey information
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Johns Hopkins University, Baltimore, Maryland, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Life expectancy of at least 12 weeks
- Adequate bone marrow, liver, and renal function
- Scheduled to undergo bronchoscopy for malignant airway obstruction as standard medical care
- Pathologically confirmed, unresectable primary or recurrent non-small cell lung cancer
- Measurable disease with obstruction into the airway
- Pathologically confirmed, unresectable primary or recurrent non-small cell lung cancer
- Patients undergo recanalization procedure of tumor during bronchoscopy
- Investigator is able to insert and deploy the Blowfish Catheter into the airway after recanalization
Exclusion criteria
- Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer
- Pregnant or nursing female subjects, or female subjects of child bearing potential who refuse to take a pregnancy test prior to their enrollment in this study
- Uncontrolled infection
- Presence or recent history of any systemic disorder or conditions, such as:
- uncontrolled hypertension
- type 1 diabetes
- severe pulmonary hypertension
- acute kidney injury
- stroke (within the last 6 month)
- myocardial infarction (within the last 3 months)
- Individuals with neurological, mental or psychiatric disorders
- Concurrent participation in another study involving investigational drugs or investigational medical devices
- Other (non-cancer) disease not stabilized within 1 month before the Screening Visit
- Known hypersensitivity to paclitaxel, Cremophor EL, or iodinated contrast media
- Any serious, uncontrolled comorbidity or condition that an Investigator believes would interfere with the intent of the study or would make participation not in the best interest of the patient Intraoperative Exclusion Criteria
- Use of pulmonary airway stents and/or ongoing or initiation of local external beam or brachytherapy radiation
- Any intraoperative complications that per the investigator's judgment increase the risk to the patient.
Treatment and study plan
Primary outcomes
-
Treatment safety
Time frame: 12 weeks
Adverse Events (AEs), Serious Adverse Events (SAEs), and all Unanticipated Adverse Device Effects (UADEs)
-
Technical success
Time frame: procedure day
Device deployment and infusion success
Secondary outcomes
-
Airway patency improvements
Time frame: 6 weeks
-
Quality of Life
Time frame: 12 weeks
Sponsors and collaborators
Lead sponsor
Mercator MedSystems, Inc.
Industry
Collaborators
- National Cancer Institute (NCI)
Registry information
Acronym: BROADWAY
Important dates
- Study start
- 2014
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Feb 19, 2014
- Registry last updated
- Apr 20, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.